Varenicline Tartrate With Telephone-Based Counseling and/or Internet-Based Counseling in Helping Adults Stop Smoking
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00301145|
Recruitment Status : Completed
First Posted : March 10, 2006
Last Update Posted : December 19, 2013
RATIONALE: Varenicline tartrate may help people quit smoking by decreasing the symptoms of nicotine withdrawal. It is not yet known whether varenicline tartrate is more effective in helping people stop smoking when given together with a telephone-based counseling program, and Internet-based counseling program, or both programs.
PURPOSE: This randomized clinical trial is studying how well giving varenicline tartrate together with a telephone-based counseling program and/or an Internet-based counseling program works in helping adults stop smoking.
|Condition or disease||Intervention/treatment||Phase|
|Unspecified Adult Solid Tumor, Protocol Specific||Behavioral: smoking cessation intervention Drug: varenicline Other: counseling intervention Other: internet-based intervention||Not Applicable|
- Determine the effectiveness of varenicline with telephone counseling vs Internet-based counseling vs telephone counseling and Internet-based smoking cessation interventions in adult smokers.
- Determine individual or group differences in patients undergoing these interventions.
- Determine heterogeneity in responsiveness in regard to the Classification and Regression Tree Analysis in patients undergoing these interventions.
- Determine the effectiveness of these interventions in regard to recruitment, implementation, barriers to treatment, exposure to intervention, satisfaction with treatment, treatment contamination, and program maintenance.
- Determine the cost-effectiveness of these interventions.
OUTLINE: This is a randomized, open-label study. Patients are randomized to 1 of 3 intervention arms.
- Arm I: Patients undergo a proactive telephone-based (PTB) smoking cessation program.
- Arm II: Patients undergo a web-based (WB) smoking cessation program.
- Arm III: Patients undergo an integrated PTB/WB smoking cessation program. Beginning 1 week before the target quit date, all patients receive oral varenicline once daily for 3 days and then twice daily for up to 12 weeks. They also receive a mailed packet containing a welcome letter, description of the intervention services offered, a privacy notice, a Free & Clear Quit Kit (comprehensive education/self-help materials including health smoking substitutions), a phone call to orient the patient to the intervention to which they are randomized, and access to a toll-free support line. All patients undergo a pre-treatment assessment (pre-quit) and 3 post-quit assessments at 21 days, 12 weeks, and 6 months after their original scheduled quit date to determine medication adherence, treatment utilization, point-prevalent smoking outcomes, and continuous nonsmoking.
PROJECTED ACCRUAL: A total of 1,200 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1200 participants|
|Masking:||None (Open Label)|
|Official Title:||Treatment of Nicotine Dependence in a Health Care Setting|
|Study Start Date :||October 2005|
|Actual Primary Completion Date :||June 2008|
|Actual Study Completion Date :||November 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00301145
|United States, California|
|Menlo Park, California, United States, 94025|
|United States, Washington|
|Center for Health Studies|
|Seattle, Washington, United States, 98101-1448|
|Free & Clear, Incorporated|
|Seattle, Washington, United States, 98104|
|Study Chair:||Gary E. Swan, PhD||SRI International|